Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07256158 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

Study acronym: FIL_PRIORITY
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv3 Show 4 more changesShow less
    • Primary completion moved earlier from Mar 1, 2033 to Dec 2029
    • Start date changed from estimate of Mar 1, 2026 to Jul 10, 2026
    • Study completion pushed from Mar 1, 2033 to Aug 2033
    • Site details revised at 38 of 38 sites
  2. Study sites: 37 to 38
    • Study title shortened, about 8 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD. Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD. The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.
Trial Details
NCT Number NCT07256158
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions
(from sponsor)		 Hodgkin Lymphoma
Related terms Hodgkin Disease
Enrollment 518 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov